Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSMNASDAQ:BPMCNASDAQ:RARENASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$102.89+1.3%$106.70$72.02▼$139.13$5.07B0.47677,064 shs650,414 shsBPMCBlueprint Medicines$128.12-0.1%$103.81$73.04▼$128.34$8.27B0.841.24 million shs3.48 million shsRAREUltragenyx Pharmaceutical$37.35+1.9%$36.37$29.59▼$60.37$3.53B0.25838,729 shs1.02 million shsZLABZai Lab$36.93-0.8%$32.70$16.01▼$44.34$4.07B0.96902,163 shs670,174 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics0.00%-3.16%-5.04%-18.85%+35.35%BPMCBlueprint Medicines0.00%-0.07%+24.39%+44.41%+20.06%RAREUltragenyx Pharmaceutical0.00%-4.94%0.00%-4.67%-0.19%ZLABZai Lab0.00%-14.18%+13.18%+5.24%+96.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXSMAxsome Therapeutics4.6399 of 5 stars4.52.00.04.51.34.20.6BPMCBlueprint Medicines1.0092 of 5 stars2.12.00.00.01.90.80.6RAREUltragenyx Pharmaceutical4.2301 of 5 stars3.53.00.03.82.42.50.6ZLABZai Lab2.0393 of 5 stars3.41.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.06Buy$172.3367.49% UpsideBPMCBlueprint Medicines 2.27Hold$128.06-0.05% DownsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$88.77137.67% UpsideZLABZai Lab 2.75Moderate Buy$47.3728.26% UpsideCurrent Analyst Ratings BreakdownLatest BPMC, RARE, AXSM, and ZLAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025BPMCBlueprint MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.006/12/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.006/10/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.006/9/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$153.00 ➝ $150.006/5/2025BPMCBlueprint MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.006/5/2025BPMCBlueprint MedicinesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.006/4/2025BPMCBlueprint MedicinesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell ➝ Hold$83.00 ➝ $129.006/3/2025BPMCBlueprint MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$132.006/3/2025AXSMAxsome TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$185.006/3/2025BPMCBlueprint MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$385.69M13.14N/AN/A$1.18 per share87.19BPMCBlueprint Medicines$508.82M16.26N/AN/A$4.70 per share27.26RAREUltragenyx Pharmaceutical$560.23M6.30N/AN/A$2.76 per share13.53ZLABZai Lab$398.99M10.21N/AN/A$7.68 per share4.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.77N/A36.49N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)BPMCBlueprint Medicines-$67.09M-$2.47N/A197.11N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)ZLABZai Lab-$257.10M-$2.49N/AN/AN/A-60.26%-33.35%-23.28%8/5/2025 (Estimated)Latest BPMC, RARE, AXSM, and ZLAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ZLABZai Lab-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million5/1/2025Q1 2025BPMCBlueprint Medicines-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics3.482.031.96BPMCBlueprint Medicines1.012.802.75RAREUltragenyx PharmaceuticalN/A2.402.24ZLABZai LabN/A3.263.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%BPMCBlueprint MedicinesN/ARAREUltragenyx Pharmaceutical97.67%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.30%BPMCBlueprint Medicines4.21%RAREUltragenyx Pharmaceutical5.50%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.24 million38.26 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableRAREUltragenyx Pharmaceutical1,29494.54 million89.34 millionOptionableZLABZai Lab1,869110.33 million104.86 millionOptionableBPMC, RARE, AXSM, and ZLAB HeadlinesRecent News About These CompaniesMission Wealth Management LP Buys Shares of 20,000 Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)June 18 at 4:14 AM | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's WhyJune 17 at 12:43 PM | marketbeat.comZai Lab (NASDAQ:ZLAB) versus Antibe Therapeutics (OTCMKTS:ATBPD) Head to Head ComparisonJune 17 at 2:25 AM | americanbankingnews.comZai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025June 13, 2025 | finance.yahoo.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Time to Buy?June 12, 2025 | marketbeat.comCantor Fitzgerald Forecasts Zai Lab FY2026 EarningsJune 11, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Sets New 1-Year High - Here's What HappenedJune 10, 2025 | marketbeat.comTwo Sigma Investments LP Trims Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)June 8, 2025 | marketbeat.comYajing Chen Sells 9,618 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockJune 5, 2025 | marketbeat.comZai Lab Limited (NASDAQ:ZLAB) CFO Sells $288,540.00 in StockJune 5, 2025 | insidertrades.comBank of America Corp DE Has $1.63 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)June 5, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's WhyJune 4, 2025 | marketbeat.comSquarepoint Ops LLC Acquires Shares of 27,961 Zai Lab Limited (NASDAQ:ZLAB)June 3, 2025 | marketbeat.comLegacy Wealth Asset Management LLC Buys Shares of 22,285 Zai Lab Limited (NASDAQ:ZLAB)June 2, 2025 | marketbeat.comMillennium Management LLC Sells 15,023 Shares of Zai Lab Limited (NASDAQ:ZLAB)June 1, 2025 | marketbeat.comZai Lab Limited (NASDAQ:ZLAB) Sees Large Drop in Short InterestJune 1, 2025 | marketbeat.comZai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 TrialMay 31, 2025 | insidermonkey.comZai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingMay 31, 2025 | businesswire.comZai Lab Announces Participation in Investor Conferences in June 2025May 30, 2025 | businesswire.comNorthern Trust Corp Increases Holdings in Zai Lab Limited (NASDAQ:ZLAB)May 29, 2025 | marketbeat.comZai Lab Limited Is Well Positioned For Long-Term GrowthMay 28, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s Watching3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsTesla Stock: Why These 2 Downgrades Are Actually a Buy SignalBy Sam Quirke | June 11, 2025View Tesla Stock: Why These 2 Downgrades Are Actually a Buy SignalBPMC, RARE, AXSM, and ZLAB Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$102.89 +1.29 (+1.27%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$101.66 -1.22 (-1.19%) As of 06/18/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Blueprint Medicines NASDAQ:BPMC$128.12 -0.11 (-0.09%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$128.14 +0.02 (+0.02%) As of 06/18/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Ultragenyx Pharmaceutical NASDAQ:RARE$37.35 +0.69 (+1.88%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$37.36 +0.02 (+0.04%) As of 06/18/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Zai Lab NASDAQ:ZLAB$36.93 -0.29 (-0.78%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$36.91 -0.02 (-0.05%) As of 06/18/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
